Appointments

Biosynth – known for supplying the life sciences industry with critical raw materials and services – has announced that Matt Gunnison has been appointed as its new CEO and Kieran Murphy has been appointed as chairman. The previous CEO, Urs Spitz, remains a key member of the board of directors.

Matt Gunnison is currently at Gamma Biosciences, where he is CEO. He cofounded Gamma Biosciences along with global investment firm KKR – which also partly owns Biosynth. He brings over 20 years of experience to Biosynth, including overseeing the acquisition and management of several growth-stage businesses as part of his time at Gamma. He has also served as head of corporate development at General Electric Co as part of GE Healthcare.

Kieran Murphy, meanwhile, currently acts as a senior advisor at KKR and as chairman of Gamma Biosciences, a position he’s held since 2022. He also brings decades of experience to the role, having formerly been president and CEO of GE Healthcare and GE Healthcare Life Sciences.

Kieran Murphy comments, “It’s a privilege to be appointed chairman of Biosynth. I am excited to work alongside Matt and the entire team as we chart the course for the company’s continued growth. Biosynth is at the forefront of innovation in the life sciences industry, and I am confident we have the right leadership and vision to drive our success forward.”

Matt Gunnison adds, “I am thrilled to join Biosynth at such an exciting time in its journey. The company has built a strong foundation under Urs’s leadership, and I look forward to working with the talented team to further accelerate our growth and innovation. Together, we will continue to deliver critical raw materials and services that drive advancements in the life sciences and make a real impact on global health outcomes.”